Goldberg Named Associate Group Chair of CALGB

Info

CHAPEL HILL, N.C. -Richard M. Goldberg, MD has been appointed to a newly-created position with the Cancer and Leukemia Group B (CALGB), a national clinical research group sponsored by the National Cancer Institute (NCI).

Dr. Goldberg, who is Physician-in-Chief of the N.C. Cancer Hospital and Chief of the Division of Hematology and Oncology at UNC-Chapel Hill School of Medicine, will serve as Associate Group Chair for Intergroup Affairs. In this role, he will help CALGB meet new NCI requirements designed to move cancer treatments from testing to approval more quickly and will serve as a primary liaison with the chairs of other cooperative clinical trials groups.

UNC Lineberger Comprehensive Cancer Center, where Dr. Goldberg is Associate Director of Clinical Research, is a member of CALGB. Founded in 1956, the CALGB brings together clinical oncologists and laboratory investigators to develop better treatments for cancer. CALGB has grown exponentially over the years into a national network of 26 university medical centers, more than 200 community hospitals and more than 3,000 oncology specialists who collaborate in clinical research studies.

These studies aim to reduce cancer occurrences and deaths from cancer, understand how differences in cancer biology relate to clinical outcomes, and develop new strategies for the early detection and prevention of cancer.

Dr. Goldberg was previously Chair of the CALGB Gastrointestinal Cancer Committee and served as Chair of the North Central Cancer Treatment Group GI Committee from 1994-2003.

Dr. Goldberg joined UNC in 2004, having previously served as Professor of Oncology at the Mayo Clinic in Rochester, Minnesota, where he also chaired the Mayo Gastrointestinal Cancer Research Program.

Dr Goldberg is a member of American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Joint Commission on Cancer (AJCC) colorectal task force. He has served as a member of the National Cancer Institute’s (NCI) GI steering committee since 2004. He is also a member of the GISC Colon Cancer Task Force, where he served as founding chair from 2004-2009.

He has been an invited reviewer for many leading medical and oncology journals, and on the editorial boards of the NCI’s Physician Data Query program, the Journal of Clinical Oncology, Clinical Colorectal Cancer, and Oncology. Dr Goldberg’s principal research interests include the evaluation of new agents for the treatment of colorectal cancer, inherited colorectal cancer syndromes, clinical trials methodology, and the role of meta-analysis in the decision making process for evidence based medicine. He has coauthored more than 200 publications.